<DOC>
	<DOCNO>NCT00060749</DOCNO>
	<brief_summary>This study evaluate whether docosahexaenoic acid ( DHA ) dietary supplementation improve macular function patient Stargardt macular dystrophy Stargardt-like macular dystrophy . Stargardt macular dystrophy recessive inherit trait cause severe form macular degeneration . ( The macula center part retina back eye responsible fine vision . ) The disorder begin late childhood progress significant decrease central vision . One early sign disorder accumulation macula fatty pigment call lipofuscin . Stargardt-like macular dystrophy dominant inherit trait involve loss central vision , begin later Stargardt macular dystrophy , accumulation lipofuscin extend beyond central region macula . DHA fatty acid essential normal brain eye development . It normally find diet , large amount . Supplements may help prevent slow progression eye disease . Patients autosomal dominant Stargardt-like macular dystrophy autosomal recessive Stargardt macular dystrophy eligible study . Candidates screen follow test procedure : - Medical history physical examination . - Blood test measure level DHA vitamin . - Eye examination : The patient 's vision eye pressure test , pupil dilate examine structure inside eye . Photographs also take . - Visual field test : The patient look tiny spot light project onto white screen ask note light appear place screen . - Electroretinogram ( ERG ) : An electrode ( small silver disk ) tap patient 's forehead . Drops give numb eye special contact lens insert eye . For first part test , patient look center black white checkerboard screen flicker 30 second time . This repeat 16 time . For second part test , patient look inside sphere , flash light flicker 20 second time . This repeat four time . The contact lenses sense small electrical signal generate retina test . Participants begin take DHA capsule placebo ( look-alike capsule active ingredient ) 1 week 3 month enrol study repeat several screen test follow-up visit schedule 3 , 6 , 9 , 12 , 15 month start take capsule . They also interview treatment side effect .</brief_summary>
	<brief_title>Effect DHA Supplements Macular Function Patients With Stargardt Macular Dystrophy Stargardt-like Macular Dystrophy</brief_title>
	<detailed_description>We propose undertake double-masked , randomize , placebo-controlled , crossover study effect docosahexaenoic acid ( DHA ) dietary supplementation subject macular dystrophy determine whether DHA improve macular function . Subjects receive either oral DHA supplementation ( 5x200 mg BID , 2,000 mg/day ) placebo . Subjects 'crossover ' opposite treatment twice study . Primary outcomes measure change macular function period without DHA supplementation . Zhang colleague find mutation gene , ELOVL4 ( elongation long chain fatty acid-4 ) , individual Stargardt-like macular dystrophy . The gene presumed function pathway synthesis long chain polyunsaturated fatty acid , include DHA . DHA major long chain polyunsaturated fatty acid retina . As North American diet poor DHA , hypothesize DHA dietary supplement might improve macular function individual ELOVL4 mutation . Since effect DHA supplementation may non-specific , propose study second cohort Stargardt macular dystrophy , different genotype involve different metabolic pathway eye , present similar phenotype . Two cohort 10 subject analysis recruit patient either Stargardt-like macular dystrophy Stargardt macular dystrophy .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>INCLUSION CRITERIA : To eligible enroll study , prospective participant must satisfy follow inclusion criterion . 1 . Understand sign inform consent . 2 . Able comply study procedure ( likely exclude participant less 10 year age , necessarily ) . Autosomal Recessive Stargardt Macular Dystrophy Participants ( must observe least one study eye ) : 3 . Have pattern inheritance indicate autosomal recessive inheritance . 4 . Have phenotype consistent diagnosis autosomal recessive Stargardt macular dystrophy include follow clinical feature : fundus examination show bilateral central maculopathy and/or fundus fleck , characteristic change intravenous fluorescein angiogram . Autosomal Dominant Stargardtlike Macular Dystrophy Participants ( must observe least one study eye ) : 5 . Have pattern inheritance indicate autosomal dominant inheritance . 6 . Have phenotype consistent diagnosis Stargardtlike macular dystrophy may include : fundus examination show bilateral central maculopathy fundus fleck confine central macula , intravenous fluorescein angiogram . EXCLUSION CRITERIA : To eligible enroll study , prospective participant must satisfy follow exclusion criterion . 1 . Have nonrecordable multifocal ERG .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 10, 2007</verification_date>
	<keyword>Stargardt</keyword>
	<keyword>Macular Dystrophy</keyword>
	<keyword>ELOVL4</keyword>
	<keyword>DHA</keyword>
	<keyword>Stargardt 's Disease</keyword>
	<keyword>Autosomal Dominant Macular Dystrophy</keyword>
	<keyword>Autosomal Recessive Macular Dystrophy</keyword>
</DOC>